期刊文献+

产ESBLs肠杆菌科细菌的检测及耐药性分析

STUDY OF ANTIBIOTIC RESISTANCE IN CLINICAL ISOLATES OF ENTEROBACTERIA PRODUCING EXTENDED-SPECTRUM BETALACTAMASES
下载PDF
导出
摘要 目的 了解产超广谱 β 内酰胺酶 (ESBLs)的肠杆菌科细菌的耐药性、耐药特点 ,指导临床用药。 方法 应用双纸片法检测 4 64株肠杆菌科细菌ESBLs,并用K B纸片扩散法测定其对 14种抗生素的耐药性。结果 阴沟肠杆菌、粘质沙雷菌、弗劳地枸橼酸杆菌、大肠埃希菌、肺炎克雷伯菌 5种肠杆菌产ESBLs的检出率分别为 4 0 .3 %、2 9.6%、2 8.6%、2 6.4 %、2 1.2 % ;5种产ESBLs的肠杆菌对氨苄西林、哌拉西林、头孢唑啉、头孢呋辛的耐药率为10 0 % ;对头孢三嗪、头孢噻肟、头孢哌酮、头孢他啶表现为敏感者占 7%~ 2 6% ;产ESBLs株与不产酶株对三代头孢的耐药率有显著差异 (P <0 .0 1) ;未见产酶株对泰能耐药。结论 检出ESBLs细菌可指导临床用药 ,对ESBLs细菌的治疗需要β 内酰胺类抗生素加酶抑制的复合制剂 。 Objictive To determine the prevalence of strains producing ESBLs among Enterobacteriaceae,and investigate the antibiotic resistance of these strains.Methods 125 strains of ESBLs producing Enterobacteriaceae were determined by a double disk synergy test and antibiotic susceptibility test by Kirby Bauer test.Results The detection rate of ESBLs producing E·cloacae,S·marcescence,C·freundii,E·coli and K·pneumoniae was 40.3%,29.6%,28.6%,26.4%,21.2%,respectively.The resistance rate of ESBLs producing strains to ampicillin,piperacillin,cefazolin,cefu roxime was 100%,the susceptibility rate to ceftriaxone,cefotaxime,cefoperazone,ceftazidime was 7~26%,lower than that of non ESBLs producing strains,showing significent difference (P<0.01).Conclusion To deal with the ESBLs producing strains,β lactama/β lactamase inhibitor combinations can be used,imipenem may be the first choice.
出处 《青海医学院学报》 CAS 2001年第3期9-11,共3页 Journal of Qinghai Medical College
关键词 肠杆菌科细菌 ESBIs 抗生素 耐药性 Enterobacteriaceae ESBLs Antibiotic Resistance
  • 相关文献

参考文献6

二级参考文献18

  • 1王辉,陈民钧,徐英春.简要介绍美国NCCLS药敏试验纸片扩散法法规(续)(1994年12月版)[J].中华医学检验杂志,1995,18(2):118-124. 被引量:136
  • 2吴永乐.新的碳青霉烯类抗生素[J].国外医药(抗生素分册),1995,16(3):178-182. 被引量:8
  • 3张致平.20世纪90年代β-内酰胺类抗生素研究开发的进展[J].国外医药(抗生素分册),1996,17(1):1-18. 被引量:12
  • 4[1]Libermore DM. Determinants of the activity of β-lactamase inhibitor combinations. J Antimicrob Chemother, 1993, 31 (Suppl A):9
  • 5[2]Jones RN, Pfaller MA,Doern GV, et al. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs:a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Inect Dis,1998,30:215
  • 6[3]Pfaller MA,Jones RN,Doern GV,et al. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Veneauela using the E test method. Diagn Microbiol Infect Dis,1998,30:45
  • 7[4]Marshall SA,Aldridge KE, Allen SD, et al. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis, 1995,21:153
  • 8[5]Klepser ME,Marangos MN ,Zhuz, et al. Comparation of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1997,41:435
  • 9[6]Shales DM, Norden C. Piperacillin-tazobactam compared to ticarcillin-clavulanate in community-acquired bacterial lower respiratory tract infection. 33rd ICAAC,New orleans, Louisianna, USA1993,Abstract 646
  • 10[7]Tan JS,Wishnow RM,Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind ,randomized ,multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicro Agent Chemothe, 1993,37:1580

共引文献403

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部